WallStreetZenWallStreetZen

NASDAQ: KTRA
Kintara Therapeutics Inc Stock

$7.05+0.21 (+3.07%)
Updated Feb 6, 2023
KTRA Price
$7.05
Fair Value Price
$19.14
Market Cap
$11.39M
52 Week Low
$3.50
52 Week High
$42.00
P/E
-0.38x
P/B
1.18x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$21.29M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.37
Operating Cash Flow
-$22M
Beta
0.84
Next Earnings
Feb 9, 2023
Ex-Dividend
N/A
Next Dividend
N/A

KTRA Overview

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KTRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

KTRA ($7.05) is undervalued by 63.17% relative to our estimate of its Fair Value price of $19.14 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KTRA ($7.05) is significantly undervalued by 63.17% relative to our estimate of its Fair Value price of $19.14 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
KTRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KTRA due diligence checks available for Premium users.

Be the first to know about important KTRA news, forecast changes, insider trades & much more!

KTRA News

Valuation

KTRA fair value

Fair Value of KTRA stock based on Discounted Cash Flow (DCF)
Price
$7.05
Fair Value
$19.14
Undervalued by
63.17%
KTRA ($7.05) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KTRA ($7.05) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KTRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

KTRA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.38x
Industry
11.5x
Market
14.99x

KTRA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.18x
Industry
5.06x
KTRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

KTRA's financial health

Profit margin

Revenue
$0.0
Net Income
-$4.6M
Profit Margin
0%
KTRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$13.2M
Liabilities
$3.6M
Debt to equity
0.37
KTRA's short-term assets ($8.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KTRA's short-term assets ($8.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KTRA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KTRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.4M
Investing
-$232.0k
Financing
$1.9M
KTRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

KTRA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
KTRA$11.39M+3.07%-0.38x1.18x
ONCR$11.38M+0.69%-0.15x0.14x
VBLT$11.37M-1.21%0.33x0.45x
CING$11.42M+2.02%-0.71x1.37x
BRTX$11.31M-1.91%-0.28x0.67x

Kintara Therapeutics Stock FAQ

What is Kintara Therapeutics's quote symbol?

NASDAQ: KTRA) Kintara Therapeutics trades on the NASDAQ under the ticker symbol KTRA. Kintara Therapeutics stock quotes can also be displayed as NASDAQ: KTRA.

If you're new to stock investing, here's how to buy Kintara Therapeutics stock.

What is the 52 week high and low for Kintara Therapeutics (NASDAQ: KTRA)?

(NASDAQ: KTRA) Kintara Therapeutics's 52-week high was $42.00, and its 52-week low was $3.50. It is currently -83.21% from its 52-week high and 101.31% from its 52-week low.

How much is Kintara Therapeutics stock worth today?

(NASDAQ: KTRA) Kintara Therapeutics currently has 1,616,146 outstanding shares. With Kintara Therapeutics stock trading at $7.05 per share, the total value of Kintara Therapeutics stock (market capitalization) is $11.39M.

Kintara Therapeutics stock was originally listed at a price of $3,400.00 in Feb 22, 2013. If you had invested in Kintara Therapeutics stock at $3,400.00, your return over the last 9 years would have been -99.79%, for an annualized return of -49.67% (not including any dividends or dividend reinvestments).

How much is Kintara Therapeutics's stock price per share?

(NASDAQ: KTRA) Kintara Therapeutics stock price per share is $7.05 today (as of Feb 6, 2023).

What is Kintara Therapeutics's Market Cap?

(NASDAQ: KTRA) Kintara Therapeutics's market cap is $11.39M, as of Feb 7, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Kintara Therapeutics's market cap is calculated by multiplying KTRA's current stock price of $7.05 by KTRA's total outstanding shares of 1,616,146.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.